Video

Dr. Zelenetz Highlights Studies From the 2012 ASH Meeting

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the trials investigating ABT-199 and ibrutinib that were presented at the 2012 American Society of Hematology (ASH) Meeting.

Andrew D. Zelenetz, MD, PhD, Vice Chair, Medical Informatics, Department of Medicine; Chief, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, discusses the trials investigating ABT-199 and ibrutinib that were presented at the 2012 American Society of Hematology (ASH) Meeting.

ABT-199 is a BCL-2 inhibitor that was analyzed in a phase I study of patients with relapsed non-Hodgkin lymphoma. The trial found that ABT-199 showed anti-tumor activity as a monotherapy in non-Hodgkin lymphoma, specifically in mantle cell lymphoma. The results, Zelenetz says, will hopefully be able to help the oncology community integrate ABT-199 into future treatment programs.

Ibrutinib, which inhibits the Bruton’s tyrosine kinase, has demonstrated activity in large B-cell lymphoma but is not approved. The results of a phase II study examining ibrutinib showed a clinically meaningful response rate in relapsed/refractory activated B cell-like diffuse large B-cell lymphoma but not in other subtypes. Zelenetz says that the results of this study provide an opportunity for future development of this agent and testing in defined populations.

<<<

View coverage from the 2012 ASH Meeting

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Karl Semaan, MD, MSc